Anjana Pillai, MD, is a board-certified gastroenterologist and transplant hepatologist who specializes in managing chronic liver diseases, complex liver transplants and hepatobiliary malignancies. She is the Medical Director of the Transplant Institute and of the Adult Liver Transplant Program. In addition, in her role as the Director of the liver tumor program, Dr. Pillai leads a team of specialists with expertise in benign and malignant liver tumors who together see patients in one location to enhance the patient experience. As a professor of medicine and surgery and a full member of the University of Chicago Medicine Comprehensive Cancer Center, she collaborates with the cancer center to provide individualized treatment options to her patients.
Dr. Pillai is also active in national and international societies that focus on advancing research and setting industry standards, including the UNOS National Liver Review Board for adult HCC and the Governing Board for the International Liver Cancer Association (ILCA). She is the past Chair of the Liver and Intestinal Community of Practice (LICOP) Executive Committee of the American Society of Transplantation (AST) and is the current chair of the Liver Cancer Special Interest Group of the American Association for the Study of Liver Diseases (AASLD). Additionally, she is the Founder and course director of HCC-LIVE, an annual conference dedicated to advancing liver cancer care. Her contributions to these organizations help shape the future of liver transplantation, liver cancer and ensure her patients benefit from the latest medical research.
University of Miami School of Medicine
Miami, FL
MD
University of Illinois Chicago
Chicago, IL
- Internal Medicine
Cleveland Clinic
Cleveland, OH
- Gastroenterology and Hepatology
Northwestern Memorial Hospital
Chicago, IL
- Transplant Hepatology
Workload, compensation, and institutional support among U.S. transplant hepatologists: Results of a national survey.
Workload, compensation, and institutional support among U.S. transplant hepatologists: Results of a national survey. Liver Transpl. 2025 Sep 11.
PMID: 40934135
Intrahepatic cholangiocarcinoma: Insights on molecular testing, targeted therapies, and future directions from a multidisciplinary panel.
Intrahepatic cholangiocarcinoma: Insights on molecular testing, targeted therapies, and future directions from a multidisciplinary panel. Hepatol Commun. 2025 Jul 01; 9(7).
PMID: 40489757
Recommendations to overcome barriers to transplant fellowship training: A report from the American Society of Transplantation Fellows Task Force.
Recommendations to overcome barriers to transplant fellowship training: A report from the American Society of Transplantation Fellows Task Force. Am J Transplant. 2025 Aug; 25(8):1601-1613.
PMID: 40373877
The association between stage migration and overall survival after radiation-based therapies in patients with hepatocellular carcinoma.
The association between stage migration and overall survival after radiation-based therapies in patients with hepatocellular carcinoma. JHEP Rep. 2025 Jul; 7(7):101434.
PMID: 40584265
Direct-acting antivirals lower mortality and recurrence in HCV-related hepatocellular carcinoma post liver resection: A multicenter international study.
Direct-acting antivirals lower mortality and recurrence in HCV-related hepatocellular carcinoma post liver resection: A multicenter international study. Surgery. 2025 Jul; 183:109396.
PMID: 40334495
Advances in Locoregional and Systemic Treatments for Hepatocellular Carcinoma.
Advances in Locoregional and Systemic Treatments for Hepatocellular Carcinoma. Gastroenterology. 2025 Sep; 169(4):585-599.
PMID: 40320088
Combined liver with other solid organ transplants: Promises, pitfalls and ethical dilemmas.
Combined liver with other solid organ transplants: Promises, pitfalls and ethical dilemmas. J Hepatol. 2025 Oct; 83(4):982-988.
PMID: 40316053
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence.
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence. JHEP Rep. 2025 Aug; 7(8):101431.
PMID: 40677696
Impact of age on clinical outcomes among patients with hepatocellular carcinoma: A systematic review and meta-analysis.
Impact of age on clinical outcomes among patients with hepatocellular carcinoma: A systematic review and meta-analysis. JHEP Rep. 2025 Jun; 7(6):101368.
PMID: 40535553
Reimagining Liver Cancer Allocation: Defining a New Vision.
Reimagining Liver Cancer Allocation: Defining a New Vision. Gastroenterology. 2025 Apr; 168(4):650-651.
PMID: 39756523